Dyadic International, Inc. (DYAI): Price and Financial Metrics
GET POWR RATINGS... FREE!
DYAI Stock Summary
- DYAI has a higher market value than merely 12.67% of US stocks; more precisely, its current market capitalization is $49,414,163.
- For DYAI, its debt to operating expenses ratio is greater than that reported by only 0.48% of US equities we're observing.
- DYAI's price/sales ratio is 19.77; that's higher than the P/S ratio of 93.92% of US stocks.
- If you're looking for stocks that are quantitatively similar to DYADIC INTERNATIONAL INC, a group of peers worth examining would be PSNL, ENTX, TARS, EYEN, and SDGR.
- Visit DYAI's SEC page to see the company's official filings. To visit the company's web site, go to www.dyadic.com.
DYAI Valuation Summary
- DYAI's price/sales ratio is 17.7; this is 247.06% higher than that of the median Healthcare stock.
- Over the past 46 months, DYAI's price/sales ratio has gone down 55.5.
Below are key valuation metrics over time for DYAI.
DYAI's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- DYAI has a Quality Grade of D, ranking ahead of 6.48% of graded US stocks.
- DYAI's asset turnover comes in at 0.074 -- ranking 281st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows DYAI's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
DYAI Stock Price Chart Interactive Chart >
DYAI Price/Volume Stats
|Current price||$1.75||52-week high||$4.28|
|Prev. close||$1.73||52-week low||$1.12|
|Day high||$1.75||Avg. volume||23,450|
|50-day MA||$1.47||Dividend yield||N/A|
|200-day MA||$2.20||Market Cap||49.99M|
Dyadic International, Inc. (DYAI) Company Bio
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd., as well as with the Israel Institute for Biological Research; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; research collaboration with Sanofi-Aventis Deutschland GmbH; research and commercialization collaboration with Serum Institute of India Pvt.; and nonexclusive research collaboration with WuXi Biologics. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Most Popular Stories View All
DYAI Latest News Stream
|Loading, please wait...|
DYAI Latest Social Stream
View Full DYAI Social Stream
Latest DYAI News From Around the Web
Below are the latest news stories about DYADIC INTERNATIONAL INC that investors may wish to consider to help them evaluate DYAI as an investment opportunity.
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms today announced that, in line with the timing announced during management’s Q3 earnings call, it has initiated dosing in its Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for the DYAI-100 COVID-19 recombinant protein re
JUPITER, Fla., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced that it received approximately $1.27 million in connection with the sale of its equity interest in Alphazyme LL
Dyadic's executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12 in San Francisco, CA USAJUPITER, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effect
“Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” Study supports: Dyadic’s anticipated First-In-Human clinical trial designed to demonstrate clinical safety and immune response in humans for its DYAI-100 COVID-19 recombinant protein RBD booster vaccine candidate.The C1-cell produced RBD-C-tag antigen strongly binds ACE2 receptors in vitro. Adjuvanted RBD-C-tag-based vaccine ca
Analysts Offer Insights on Healthcare Companies: Satsuma Pharmaceuticals (STSA) and Dyadic International (DYAI)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Satsuma Pharmaceuticals (STSA – Research Report) and Dyadic International (DYAI – Research Report) with bullish sentiments. Satsuma Pharmaceuticals (STSA) In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Satsuma Pharmaceuticals, with a price target of $13.00. The company's shares closed last Monday at $0.79. According to TipRanks.
DYAI Price Returns